StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 11 Sep 2026 07:00:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Spectral Medical gets FDA feedback on PMX device application http://www.streetinsider.com/FDA/Spectral+Medical+gets+FDA+feedback+on+PMX+device+application/27050648.html <p>Spectral Medical Inc. (TSX: EDT) said it held an in-person 100-day meeting with the U.S. Food and Drug Administration regarding its Premarket Approval application for its Toraymyxin device, known as PMX, receiving a deficiency letter from the FDA prior to the meeting.</p> <p>The FDA issued the deficiency letter as part of its standard substantive PMA review process, identifying items that require additional information, analyses, testing, and clarification. The company said the FDA did not request an additional clinical trial as part of the response to the deficiency letter.</p> <p>Spectral said it came away from the meeting with a clearer understanding of the http://www.streetinsider.com/FDA/Spectral+Medical+gets+FDA+feedback+on+PMX+device+application/27050648.html Fri, 11 Sep 2026 07:00:17 -0400 EDT Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA http://www.streetinsider.com/Press+Releases/Spectral+Medical%C2%A0Provides+Update+Following+In-Person+FDA+100-Day+Meeting+for+PMX+PMA/27050639.html <p align="center"><strong><em><em>• Company gains further clarity on the additional information required to advance its PMA review</em></em></strong><br/></p> <p align="center"><strong><em><em>• FDA did not request an additional clinical trial following its 100-day review of the PMA application</em><br/></em></strong></p> <p align="center"><strong><em><em>• Company does not currently expect a material change to its overall regulatory timeline</em></em></strong><br/></p> <p align="justify">TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT</strong>), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration (“FDA”) http://www.streetinsider.com/Press+Releases/Spectral+Medical%C2%A0Provides+Update+Following+In-Person+FDA+100-Day+Meeting+for+PMX+PMA/27050639.html Fri, 11 Sep 2026 07:00:00 -0400 EDT Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA http://www.streetinsider.com/Globe+Newswire/Spectral+Medical%C2%A0Provides+Update+Following+In-Person+FDA+100-Day+Meeting+for+PMX+PMA/27050639.html <p align="center"><strong><em><em>• Company gains further clarity on the additional information required to advance its PMA review</em></em></strong><br/></p> <p align="center"><strong><em><em>• FDA did not request an additional clinical trial following its 100-day review of the PMA application</em><br/></em></strong></p> <p align="center"><strong><em><em>• Company does not currently expect a material change to its overall regulatory timeline</em></em></strong><br/></p> <p align="justify">TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT</strong>), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration (“FDA”) http://www.streetinsider.com/Globe+Newswire/Spectral+Medical%C2%A0Provides+Update+Following+In-Person+FDA+100-Day+Meeting+for+PMX+PMA/27050639.html Fri, 11 Sep 2026 07:00:00 -0400 EDT Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Press+Releases/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html <p align="justify">TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- <strong>Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),</strong> a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update.</p> <p align="justify">The second quarter of 2026 marked a significant milestone in the Company's evolution as Spectral completed its U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA") application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA's substantive review process following acceptance of http://www.streetinsider.com/Globe+Newswire/Spectral+Medical+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26887517.html Fri, 07 Aug 2026 07:30:00 -0400 A.06822034 A.20613440 EDT O.00188458 O.00673989 O.20026344 Ericsson reports second quarter results 2026 http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/Press+Releases/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Ericsson reports second quarter results 2026 http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ --</p> <p><b>Strategic highlights – disciplined execution and margin resilience</b></p><ul type="disc"><li>Adjusted gross margin of 48.4%, supported by solid operational execution and improved margins in Mobile Networks.</li><li>Strong net cash position supporting continued investments and capital returns, with <money>SEK 8.2</money> b. returned to shareholders in Q2.</li><li>Demonstrated AI-enabled drone sensing and tracking using existing cell towers at a <location value="LS/us.tx" idsrc="xmltag.org" >Texas</location> stadium during a major global sporting event.</li></ul><p><b>Financial highlights – solid financial performance</b></p><ul type="disc"><li>Reported sales were <money>SEK 52.7</money> (56.1) b. Organic* sales decreased by -1%* YoY primarily due to lower IPR licensing revenues, http://www.streetinsider.com/PRNewswire/Ericsson+reports+second+quarter+results+2026/26763603.html Tue, 14 Jul 2026 01:37:00 -0400 00 AM EDT ERIC-B Invitation to media and analyst briefing for Ericsson Q2 2026 report http://www.streetinsider.com/Press+Releases/Invitation+to+media+and+analyst+briefing+for+Ericsson+Q2+2026+report/26722902.html <div class="xn-content"> <ul type="disc"><li>Report to be released at approximately <chron>7:00 AM CEST</chron> on <chron>July 14, 2026</chron></li><li>One live video webcast for analysts, investors and journalists at <chron>9:00 AM CEST</chron></li></ul><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) financial report for the second quarter 2026 will be published at approximately <chron>7:00 AM CEST</chron> on <chron>July 14, 2026</chron>. The company will issue a press release with the complete financial report attached, including tables, in PDF format. Following publication of the press release, the financial report will be available on Ericsson's website: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4724308-1&h=3283538930&u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Finvestors&a=https%3A%2F%2Fwww.ericsson.com%2Fen%2Finvestors" target="_blank" rel="nofollow">https://www.ericsson.com/en/investors</a></p> <p>President and CEO <person>Börje Ekholm</person> http://www.streetinsider.com/Press+Releases/Invitation+to+media+and+analyst+briefing+for+Ericsson+Q2+2026+report/26722902.html Thu, 02 Jul 2026 02:26:00 -0400 00 AM EDT ERIC ERIC-B ERICA O.06119320 Invitation to media and analyst briefing for Ericsson Q2 2026 report http://www.streetinsider.com/Press+Releases/Invitation+to+media+and+analyst+briefing+for+Ericsson+Q2+2026+report/26722902.html <div class="xn-content"> <ul type="disc"><li>Report to be released at approximately <chron>7:00 AM CEST</chron> on <chron>July 14, 2026</chron></li><li>One live video webcast for analysts, investors and journalists at <chron>9:00 AM CEST</chron></li></ul><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) financial report for the second quarter 2026 will be published at approximately <chron>7:00 AM CEST</chron> on <chron>July 14, 2026</chron>. The company will issue a press release with the complete financial report attached, including tables, in PDF format. Following publication of the press release, the financial report will be available on Ericsson's website: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4724308-1&h=3283538930&u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Finvestors&a=https%3A%2F%2Fwww.ericsson.com%2Fen%2Finvestors" target="_blank" rel="nofollow">https://www.ericsson.com/en/investors</a></p> <p>President and CEO <person>Börje Ekholm</person> http://www.streetinsider.com/Press+Releases/Invitation+to+media+and+analyst+briefing+for+Ericsson+Q2+2026+report/26722902.html Thu, 02 Jul 2026 02:26:00 -0400 00 AM EDT ERIC ERIC-B ERICA O.06119320